<DOC>
	<DOCNO>NCT02353585</DOCNO>
	<brief_summary>The present study monitor explore acute neurovascular emergency patient treat NOACs compare treatment VKAs . The primary aim study : ( 1 ) To investigate characteristic , management outcome intracranial hemorrhage ( ICH ) patient treat NOAC compare VKA . ( 2 ) To investigate management outcome patient acute ischaemic stroke NOAC compare VKA .</brief_summary>
	<brief_title>Novel Oral Anticoagulants Stroke Patients</brief_title>
	<detailed_description>Background : For decade , oral anticoagulation vitamin K antagonist ( VKA ) sole option treatment variety disease like venous thrombosis , pulmonary embolism prevention stroke patient atrial fibrillation . Despite clinical efficacy , treatment VKA associate multiple well-known limitation , include significant risk major hemorrhage ( especially intracerebral hemorrhage ) , food drug interaction , need continue coagulation monitor dose control . Recent randomise control trial ( RCT ) provide promising result novel oral anticoagulant ( NOAC ) exhibit limitation VKA . Especially stroke prevention patient atrial fibrillation , NOAC show comparable even well protective efficacy cause less intracerebral hemorrhage ( ICH ) . Eventually , lead marketing approval Apixaban , Rivaroxaban Dabigatran stroke prevention patient atrial fibrillation Swiss Health Authority ( Swissmedic ) . Even though trial report occurrence acute ischemic stroke intracerebral hemorrhage patient treatment NOAC , limit data case report publish far . Thus , aspects concern treatment decision concepts management acute ischemic stroke NOAC address trial ; particular , use acute revascularisation therapy like intravenous thrombolysis ( IVT ) intra-arterial treatment ( IAT ) remain unanswered . Furthermore , characteristic , management outcome ICH treatment NOAC address . Thus , information relevant aspects management acute neurovascular emergency NOACs remain scarce . Aims : The present study monitor explore acute neurovascular emergency patient treat NOACs compare treatment VKAs . The primary aim study : ( 1 ) To investigate characteristic , management outcome intracranial hemorrhage ( ICH ) patient treat NOAC compare VKA . ( 2 ) To investigate management outcome patient acute ischaemic stroke NOAC compare VKA . Methodology : We launch observational , multi-center ( Switzerland Europe ) registry . The lead coordinating center locate Stroke Center University Hospital Basel . The following group patient admit Stroke Unit one participating center enrol : A ) Patients ICH occur treatment NOAC ( last intake &lt; 48 hour ) VKA B ) Patients acute ischaemic stroke occur treatment NOAC ( last intake &lt; 48 hour ) VKA .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Intracranial Hemorrhages</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Patients ICH occur treatment NOACs ( last intake &lt; 48 hour ) VKAs indication ; Patients acute ischaemic stroke occur treatment NOACs ( last intake &lt; 48 hour ) VKAs indication . The patient , opinion investigator , unlikely comply clinical study protocol unsuitable reason . Patients &lt; 18 year age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>vitamin K-antagonist</keyword>
	<keyword>novel oral anticoagulant</keyword>
	<keyword>apixaban</keyword>
	<keyword>dabigatran</keyword>
	<keyword>rivaroxaban</keyword>
	<keyword>edoxaban</keyword>
	<keyword>direct oral anticoagulant</keyword>
</DOC>